Assist. Prof. Dr. Changtong YANG | Medicinal Chemistry | Best Researcher Award

Posted on by sciencefather

Assist. Prof. Dr. Changtong YANG | Medicinal Chemistry | Best Researcher Award

Assist. Prof. Dr. Changtong YANG , Medicinal Chemistry,  Radiochemist/Chemist at Singapore General Hospital, Singapore

Dr. Chang-Tong Yang is a renowned radiochemist based in Singapore, specializing in radiopharmaceuticals and molecular imaging. He currently serves as an Assistant Professor in the Radiological Science Academic Clinical Programme at Duke-NUS Medical School and as a Radiochemist at Singapore General Hospital. With over two decades of experience, Dr. Yang has made significant contributions to the development of nuclear imaging probes and radiolabeled therapeutics. His research career spans prestigious institutions, including Nanyang Technological University and A*STAR. Dr. Yang is internationally recognized for advancing nanomaterial probes and novel radiolabeling strategies. He has authored impactful publications in top-tier journals, reflecting his innovation in theranostics, radiochemistry, and nanomedicine. With a strong background in academic and clinical research, Dr. Yang continues to shape the future of molecular imaging for personalized medicine. His global education and interdisciplinary expertise make him a leading figure in translational radiochemistry research.

Professional Profile : 

Orcid

Scopus 

Summary of Suitability for Award:

Dr. Chang-Tong Yang exemplifies the qualities of a “Best Researcher Award” recipient. His innovative contributions to radiochemistry and molecular imaging, combined with a strong publication record, interdisciplinary leadership, and global training, establish him as a trailblazer in translational medical research. His work is not only scientifically rigorous but also clinically impactful, directly advancing the field of nuclear medicine. Therefore, he is highly recommended for recognition as a top-tier researcher deserving of this award.

🎓Education:

Dr. Chang-Tong Yang received his Ph.D. in Chemistry from the National University of Singapore (1998–2002), where he laid the foundation for his career in radiochemistry. He further enhanced his expertise with postdoctoral fellowships at three prestigious U.S. institutions: University of Iowa (2003–2005), University of Michigan (2005–2006), and Purdue University (2006–2007), focusing on chemistry and health sciences. These formative years provided Dr. Yang with a multidisciplinary perspective in synthetic chemistry, radiopharmaceutical development, and imaging sciences. His international training exposed him to cutting-edge methodologies and collaborative projects across biomedical research, which he has since translated into innovative imaging solutions. The combination of rigorous education and hands-on research across these top institutions shaped his ability to bridge fundamental science with clinical applications, particularly in nuclear medicine and molecular imaging.

🏢Work Experience:

Dr. Chang-Tong Yang brings extensive professional experience across both academic and clinical research settings. He is currently an Assistant Professor at Duke-NUS Medical School (2020–present) under the Radiological Science ACP, focusing on radiopharmaceutical sciences. Concurrently, he serves as a Radiochemist at Singapore General Hospital (2018–present) in the Department of Nuclear Medicine & Molecular Imaging, where he translates research into clinical practice. Prior to that, he worked as a Senior Scientist at Nanyang Technological University (2014–2018), contributing to molecular imaging initiatives within the Lee Kong Chian School of Medicine. He also held a Senior Scientist role at A*STAR’s Singapore Bio-Imaging Consortium (2007–2014), leading various radiochemistry research programs. Across these roles, Dr. Yang has developed and validated imaging agents, optimized radiolabeling techniques, and led translational studies that impact diagnostic imaging and therapeutic strategies. His multidisciplinary engagements underscore his pivotal role in bridging chemistry and medicine.

🏅Awards: 

While specific awards are not listed in the available data, Dr. Chang-Tong Yang’s extensive contributions to radiopharmaceuticals and molecular imaging reflect a highly respected and impactful career. His appointments at top institutions such as Duke-NUS, A*STAR, and Singapore General Hospital indicate peer recognition and institutional trust. His publications in reputed journals such as Molecules, Nanomaterials, and Drug Discovery Today highlight his standing in the scientific community. His ongoing leadership roles and collaboration with clinicians further underscore professional acknowledgment of his expertise. Dr. Yang’s selection for multiple postdoctoral positions at prestigious U.S. institutions—University of Iowa, University of Michigan, and Purdue University—suggests early recognition of his academic promise. His interdisciplinary contributions to nuclear medicine, nanotechnology, and molecular imaging may have earned him internal institutional awards, research grants, and invitations to present at scientific forums, which commonly accompany such roles.

🔬Research Focus:

Dr. Chang-Tong Yang’s research is centered on radiopharmaceutical science, with a strong emphasis on the development of molecular imaging probes and radiolabeled nanomaterials for diagnostic and therapeutic applications. His expertise lies in designing novel radioisotope-labeled compounds for use in nuclear medicine imaging techniques such as PET and SPECT, targeting cancer and other pathological conditions. He is particularly interested in enhancing the in vivo behavior of nanomaterial-based agents, improving tumor targeting, retention, and safety. Dr. Yang also explores the biocompatibility and stability of these probes, including how formulation and labeling protocols influence their function. His translational work bridges laboratory innovations with clinical imaging requirements, enabling personalized diagnostics and theranostic approaches. Furthermore, he investigates radiochemical compatibility in clinical settings, such as the mixing of imaging agents with contrast media, which supports safe and effective imaging protocols. His work integrates chemistry, imaging, and clinical practice seamlessly.

Publication Top Notes:

1. pH-Induced In Situ Aggregation of Cu₂₋ₓSe-POED with Extended Tumor Retention for Enhanced Chemodynamic/Photothermal Therapy

2. Standard Radio-Iodine Labeling Protocols Impaired the Functional Integrity of Mesenchymal Stem/Stromal Cell Exosomes

3. Radiolabeled Liposomes for Nuclear Imaging Probes

4. Radiochemical Feasibility of Mixing of 99mTc-MAA and 90Y-Microspheres with Omnipaque Contrast

5. Nanomaterial Probes for Nuclear Imaging

6. Positron Emission Tomographic Imaging in Drug Discovery

7. An In Vivo Study of a Rat Fluid-Percussion-Induced Traumatic Brain Injury Model with [11C]PBR28 and [18F]flumazenil PET Imaging

8. Gadolinium-Based Bimodal Probes to Enhance T1-Weighted Magnetic Resonance/Optical Imaging

9. Activatable Cell-Penetrating Peptide Conjugated Polymeric Nanoparticles with Gd-Chelation and Aggregation-Induced Emission for Bimodal MR and Fluorescence Imaging of Tumors

10. Dealing with PET Radiometabolites

11. PET-MR and SPECT-MR Multimodality Probes

 

Assoc. Prof. Dr. Ningbo Li | Medicinal Chemistry | Best Researcher Award

Posted on by sciencefather

Assoc. Prof. Dr. Ningbo Li | Medicinal Chemistry | Best Researcher Award

Assoc. Prof. Dr. Ningbo Li , Medicinal Chemistry , Shanxi Medical University, China

Dr. Ningbo Li is an accomplished Associate Professor at the School of Basic Medical Sciences, Shanxi Medical University, with a strong academic foundation and a passion for cancer research. With a doctorate in Organic Chemistry from Hunan University, Dr. Li has built a reputable career in green synthesis, targeted nano-drug delivery systems, and near-infrared fluorescent probes molecule for cancer diagnostics and therapy. He has led over 10 national and provincial research projects, published 46 SCI-indexed papers, and holds 5 authorized patents. Dr. Li also contributes to academia through textbooks and serves as a Young Editorial Board Member of Journal of Xiangtan University. His collaborations span leading institutions like Hunan University and Nankai University. With 863 citations and rising influence, Dr. Li is committed to pioneering innovative, low-toxicity cancer therapeutics and translating lab findings into clinical advances.

Professional Profile : 

Orcid   

Scopus 

Summary of Suitability for Award:

Dr. Ningbo Li, Associate Professor at Shanxi Medical University, has demonstrated exceptional research productivity and innovation in the fields of organic chemistry, nanomedicine, and cancer therapeutics. With over 50 SCI-indexed publications, 5 authorized patents, and leadership on more than 10 national and provincial-level research projects, Dr. Li has made significant contributions to targeted cancer treatment and green synthesis of anti-tumor agents. His pioneering work on magnetic nano-drug delivery systems and near-infrared fluorescent probes molecule showcases translational potential for clinical applications in oncology. Furthermore, his involvement in academic book publications, editorial duties, and inter-institutional collaborations reflects both leadership and scholarly impact. With a citation index of 863 and consistent innovation through funded research, Dr. Li exemplifies the qualities of a top-tier researcher. Dr. Ningbo Li is highly suitable for the “Best Researcher Award”, as he meets and exceeds the criteria in terms of research excellence, innovation, scientific impact, and societal relevance. His dedication to advancing cancer research through interdisciplinary chemistry and his strong track record in publications, patents, and funded projects make him a deserving and outstanding candidate for this prestigious recognition

🎓Education:

Dr. Ningbo Li’s academic journey began with a Bachelor’s degree in Chemistry from Shanxi Datong University (2005–2009). He pursued his postgraduate studies at Hunan University, earning a Master’s degree (2009–2012) and subsequently a Ph.D. in Organic Chemistry (2012–2015). His academic training emphasized organometallic chemistry, chiral complex synthesis, and catalysis, laying the groundwork for his future research in drug development and nanomedicine. During his doctoral studies, Dr. Li specialized in chiral Lewis acids, exploring their role in asymmetric synthesis—an area critical to pharmaceutical innovation. His graduate work was pivotal in shaping his later focus on bio-compatible metal complexes and tumor-targeted drug delivery platforms. The integration of organic synthesis with biomedical applications became a hallmark of his educational path, culminating in a multidisciplinary approach that bridges chemistry, nanotechnology, and medical science.

🏢Work Experience:

Dr. Ningbo Li began his academic career as a Lecturer (2015–2018) at the School of Basic Medical Sciences, Shanxi Medical University, where he conducted interdisciplinary research and mentored students. In December 2018, he was promoted to Associate Professor, reflecting his growing contributions to research and teaching. With over a decade in academia, he has supervised numerous graduate projects and continues to develop innovative strategies for targeted cancer therapy using nanomaterials and fluorescent probes. Dr. Li has consistently received competitive research funding from the National Natural Science Foundation of China and the Shanxi Provincial Science Foundations. He also actively contributes to national teaching excellence through authorship in leading organic chemistry textbooks. His dedication to both scientific advancement and student development underscores a career that blends high-impact research with academic leadership in medical and chemical sciences.

🏅Awards: 

While specific named awards are not detailed, Dr. Ningbo Li’s academic honors are evident through his prestigious research grants, editorial board appointment, and book contributions. He is the Principal Investigator for multiple national-level research projects, including NSFC Young Scholar Awards, which are highly competitive and indicative of early-career excellence. His appointment as a Young Editorial Board Member of the Journal of Xiangtan University (Natural Science Edition) further reflects his scientific influence and peer recognition. Dr. Li’s patents on chiral zirconium and titanium complexes also highlight his innovative contributions to chemical synthesis. Moreover, his extensive publishing record and the high citation index (863) attest to the impact of his research in organic and medicinal chemistry. Through his involvement in writing authoritative textbooks used in higher education, Dr. Li has contributed significantly to the academic development of students and educators in China.

🔬Research Focus:

Dr. Ningbo Li’s research is centered on the interdisciplinary interface of organic chemistry, nanotechnology, and cancer therapeutics, with a strong emphasis on green and sustainable chemistry. His primary focus lies in the design and synthesis of functionalized magnetic nanocomposites and near-infrared fluorescent probe molecules for the precise diagnosis and targeted treatment of malignant tumors. By engineering magnetic-targeted nano-drug delivery systems, his team aims to achieve site-specific drug accumulation, minimizing systemic toxicity and enhancing therapeutic efficacy. Another key area involves the green synthesis of novel bioactive compounds, particularly chiral organometallic complexes, which exhibit promising anti-tumor properties. His group also explores chiral Lewis acids as catalysts in asymmetric reactions, crucial for the development of structurally complex pharmaceuticals. Dr. Li’s research is highly translational, striving to bridge the gap between bench and bedside by accelerating the clinical application of biocompatible, efficient, and low-toxicity cancer therapeutics rooted in advanced chemical innovation.

Publication Top Notes:

1. g-C₃N₄-Based Heterogeneous Photocatalyzed Synthesis and Evaluation of Antitumor Activities of Fluoroalkylated 4H-Pyrido[1,2-a]pyrimidin-4-ones

2. Magnetic Nanocarriers for pH/GSH/NIR Triple-Responsive Drug Release and Synergistic Therapy in Tumor Cells

3. GSH-Responsive Magnetic Mesoporous Silica Nanoparticles for Efficient Controlled Drug Delivery in Tumor Cells

 

​

Dr. Lemlem Gebremariam Aregawi | Medicinal Chemistry | Best Researcher Award

Posted on by sciencefather

Dr. Lemlem Gebremariam Aregawi | Medicinal Chemistry | Best Researcher Award

Dr. Lemlem Gebremariam Aregawi , Medicinal Chemistry , PhD Candidate at University of Debrecen, Hungary

Lemlem Gebremariam Aregawi is an Ethiopian health professional and researcher currently pursuing a Ph.D. in Nutritional Sciences at the University of Debrecen, Hungary. With over a decade of academic and clinical experience, she has made significant contributions to public health, particularly in the areas of reproductive health, clinical nutrition, and functional gastrointestinal disorders. She served in academic, research, and leadership roles at Adigrat University and Mekelle University in Ethiopia before moving to Hungary on a prestigious scholarship. Her current research explores the therapeutic potential of natural compounds like ginger, and she has presented at numerous international scientific conferences. Lemlem is a published author with more than 19 scientific papers in peer-reviewed journals, and several are currently under review. She has also served as an external examiner for multiple universities. Her multidisciplinary expertise bridges laboratory science, clinical practice, and public health interventions with a strong focus on evidence-based approaches.

Professional Profile :         

Orcid 

Summary of Suitability for Award:

Dr. Lemlem Gebremariam Aregawi is an accomplished Ethiopian researcher in Nutritional Sciences, currently pursuing her Ph.D. at the University of Debrecen, Hungary. Her dedication to advancing clinical nutritional research, particularly involving ginger supplementation and gastrointestinal health, has resulted in over 19 peer-reviewed publications, with multiple clinical trials and systematic reviews in high-impact journals such as Current Therapeutic Research, Advances in Integrative Medicine, and Clinical Nutrition Open Science. Her work is pioneering in its translational focus on using natural compounds to improve public health outcomes. Given her extensive research output, commitment to evidence-based public health interventions, and international academic footprint, Dr. Lemlem Gebremariam Aregawi is a highly suitable candidate for the “Best Researcher Award”. Her work exemplifies the integration of scientific rigor, clinical relevance, and community health impact—making her an outstanding researcher deserving of global recognition.

🎓Education:

Lemlem Gebremariam Aregawi is a Ph.D. candidate in Nutritional Sciences at the University of Debrecen, Hungary (2019–present), where she is conducting clinical trial-based research focusing on dietary interventions and gastrointestinal health. She earned her Master of Public Health in Reproductive Health from Mekelle University, Ethiopia (2011–2013), gaining deep insights into maternal and child health and community-based healthcare strategies. Prior to that, she completed her Bachelor of Science in Medical Laboratory Technology at Jimma University, Ethiopia (2004–2006), where she developed solid clinical and laboratory diagnostic skills. Her academic journey is enriched with various specialized trainings from institutions such as Virge University in the Netherlands, and multiple pedagogical certifications from programs sponsored by USAID and the Ethiopian Ministry of Education. Her education reflects a rich integration of scientific research, health promotion, laboratory diagnostics, and public health practice—laying a strong foundation for her ongoing research and academic pursuits in nutritional science.

🏢Work Experience:

Lemlem Gebremariam Aregawi has accumulated diverse experience in academia, healthcare, and research over nearly two decades. Since 2019, she has been a Ph.D. researcher at the University of Debrecen, Hungary, working on clinical trials evaluating the nutritional effects of ginger. Prior to this, she served as Assistant Professor and Head of Research and Community Services at Adigrat University, Ethiopia (2014–2019), where she also taught public health and coordinated community programs. She worked briefly as a Clinical Laboratory Expert at Ayder Comprehensive Specialized Hospital, Mekelle University (2013–2014), and previously as Assistant Lecturer and Department Head at Mekelle Health Sciences College (2007–2011). Her early career began as a Medical Laboratory Technologist at Axum St. Merry Hospital (2006–2007). She has also served as an external examiner at Mekelle and Axum Universities. Lemlem’s roles span education, laboratory diagnostics, health systems strengthening, and nutritional research, reflecting her multidisciplinary expertise and leadership.

🏅Awards: 

Lemlem Gebremariam Aregawi has been recognized for her academic excellence, leadership, and commitment to public health. She is a recipient of a competitive international scholarship to pursue her Ph.D. studies in Hungary, highlighting her research potential and academic distinction. Throughout her career in Ethiopia, she earned accolades for her outstanding contributions as Head of Research and Community Services at Adigrat University. Lemlem has also been selected as an external examiner for both undergraduate and postgraduate students, reflecting her academic credibility and peer recognition. She has completed prestigious international training, including a pre-doctoral program at Virge University, Amsterdam. Additionally, she received multiple certifications from USAID-sponsored initiatives and Ethiopia’s Ministry of Education, including Training of Trainers (ToT) certifications on sexual and reproductive health, curriculum development, and biosafety. These honors and professional development achievements underscore her commitment to quality education, public health, and global scientific collaboration.

🔬Research Focus:

Lemlem Gebremariam Aregawi’s research centers on the role of nutritional interventions—particularly ginger—in preventing and managing chronic gastrointestinal conditions and metabolic disorders. As a Ph.D. candidate, she is currently engaged in clinical trials investigating the efficacy, safety, and quality-of-life impacts of ginger supplementation in patients with functional dyspepsia. Her broader interests include the therapeutic role of bioactive compounds in disease prevention, integrative medicine, reproductive health, and public health nutrition. She has authored several systematic reviews on ginger’s pharmacological effects, including its impact on body weight, gastrointestinal malignancies, diabetes mellitus, and inflammatory bowel disease. Lemlem’s work bridges clinical nutrition, public health, and biomedical sciences, offering evidence-based insights into the dietary management of chronic diseases. Her multidisciplinary approach enables her to evaluate both biological mechanisms and public health implications of nutritional therapies, with the ultimate goal of translating scientific findings into practical dietary recommendations and health policies.

Publication Top Notes:

“Ginger’s Nutritional Implication on Gastrointestinal Health”

“Evaluation of Adverse Effects and Tolerability of Dietary Ginger Supplementation in Patients with Functional Dyspepsia”

“Effects of Ginger Supplementation on Quality of Life in Patients with Functional Dyspepsia: An Open-Label, Clinical Trial”

“Preventive and Therapeutic Effects of Ginger on Bowel Disease: A Review of Clinical Trials”

“The Effect of Ginger Supplementation on the Improvement of Dyspeptic Symptoms in Patients With Functional Dyspepsia”

“Ginger Constituents and Its Effects on Gastrointestinal Malignancies: A Review of Clinical Trials”

“Assessment of Service Satisfaction and Associated Status Among Women Who Have Given Birth in Adigrat General Hospital, Ethiopia”

“Prevalence and Determinants of Modern Contraceptive Utilization Among Women in the Reproductive Age Group in Edaga-Hamus Town, Eastern Zone, Tigray Region, Ethiopia”

 

 

Prof. Belgin Coşge Şenkal | Biochemistry | Best Researcher Award

Posted on by sciencefather

Prof. Belgin Coşge Şenkal | Biochemistry | Best Researcher Award

Prof. Belgin Coşge Şenkal , Biochemistry , Yozgat Bozok University , Turkey

Professor Belgin Coşge Şenkal is a distinguished academic in the field of agricultural sciences, specializing in arable crops and plant breeding. She is currently a faculty member at Bozok University’s Faculty of Agriculture in Yozgat, Turkey. Throughout her career, Professor Şenkal has made significant contributions to the study of medicinal plants and aromatic plants, oil crops, and plant breeding. Her research has garnered substantial recognition, with over 1,400 citations, reflecting her influence in the scientific community. ​

Professional Profile :         

Orcid

Scopus 

Summary of Suitability for Award:

Professor Belgin Coşge Şenkal is a highly accomplished academician and researcher in the field of agricultural sciences, with a specialization in plant breeding, medicinal plants and aromatic plants, and oil crops. Her extensive research has been instrumental in advancing knowledge in these critical areas of agronomy, particularly under the ecological conditions of Turkey. Based on her strong publication record, high citation impact, dedicated mentorship, and contributions to sustainable agricultural practices, Professor Belgin Coşge Şenkal is highly suitable for the “Best Researcher Award.” Her pioneering work in medicinal and aromatic plants, oil crops, and plant breeding has had a significant influence on modern agricultural practices and natural product research. She exemplifies the qualities of a visionary and impactful researcher, making her a deserving candidate for this prestigious recognition.

🎓Education:

Professor Şenkal’s academic journey began with a Bachelor’s degree from Ankara University’s Faculty of Agriculture in 1994.She then pursued a Master’s degree at the same institution, completing her thesis in 1996 on the selection of genetically male-sterile sunflower lines and their impact on seed yield. In 2001, she earned her Ph.D. with a dissertation focusing on the effects of natural pollination on the yield and yield components of genetically male-sterile sunflower hybrids. ​

🏢Work Experience:

Professor Şenkal has held various academic positions, including Assistant Professor and Associate Professor roles at Abant Izzet Baysal University. In 2016, she was appointed as a Professor at Bozok University, where she continues to teach and conduct research. Her mentorship has guided numerous graduate students, supervising over 20 theses on topics ranging from the effects of salicylic acid on coriander growth to the impact of different sowing times on camelina yield. ​

🏅Awards: 

Specific details about Professor Şenkal’s awards and honors are not readily available in the provided information. However, her extensive publication record, significant citation count, and progression to a full professorship indicate a high level of recognition and respect in her field. Her involvement in numerous research projects and her role in supervising graduate students further underscore her contributions to agricultural sciences.​

🔬Research Focus:

Professor Şenkal’s research primarily revolves around medicinal plants and aromatic plants, oil crops, plant breeding, essential oils, and biological activity. She has investigated the effects of various treatments on plant growth and yield, such as the impact of salicylic acid on coriander and the influence of different phosphorus doses on essential oil content. Her work aims to enhance the understanding and cultivation of these plants, contributing to advancements in agricultural practices. ​

Publication Top Notes:

 Evaluation of antioxidant, antimicrobial, enzyme inhibition activity, and cell viability capacity of Hypericum heterophyllum Vent., an endemic species in Turkey’s Flora

Investigation of the Usability of Biodiesel Produced from Coriander (Coriandrum sativum L.) Gürbüz Registered Variety Crude Oil in Diesel Engines

​The Impact of Morpho- and Onto-Genetic Variation on Essential Oil Profile of Hypericum heterophyllum Vent., an Endemic Species in Turkey’s Flora​

Impacts of essential oil and extracts obtained from coriander cultivars (Coriandrum sativum L.) on some important pathogenic bacteria

Biological activities of different plant species belonging to the Asteraceae family

Fatty Acid Composition of Seed Oil from Cocklebur (Xanthium strumarium Subsp. strumarium) Grown in Turkey

Evaluation of Seedling Development and Physical Characteristics, Viability and Germination of Seeds in Some Lamiaceae Taxa

Farklı fosfor dozlarının kişniş (Coriandrum sativum L.) bitkisinde verim, verim özellikleri ve uçucu yağ oranı üzerine etkileri

Phytochemical composition of wild lemon balm (Melissa officinalis L.) from the flora of Bulgaria

Hypericum taxa of Turkey’s flora and intra-population variation of morpho-agronomic traits in H. heterophyllum Vent., an endemic species

Determination of essential oil components, mineral matter, and heavy metal content of Salvia virgata Jacq. grown in culture conditions

The Effect of Cuttings Stages on Components and Content of Essential Oils from Salvia viridis L.

 

 

 

Prof. Dr. Pengwei Zhao | Medicinal Chemistry | Best Researcher Award

Posted on by sciencefather

Prof. Dr. Pengwei Zhao | Medicinal Chemistry | Best Researcher Award

Prof. Dr. Pengwei Zhao | Medicinal Chemistry | Ph.D., Master’s Supervisor at Inner Mongolia Medical University, School of Basic Medical Sciences, China 

Dr. Pengwei Zhao is a Professor at the School of Basic Medical Sciences, Inner Mongolia Medical University, he serves as a master’s supervisor and holds various academic positions. He is a member of the Jiusan Society and actively contributes to scientific research as a registered reviewer for Medical Science Monitor and Chinese Journal of Tissue Engineering Research. He is also a youth editorial board member of Modern Oncology and a director of the Inner Mongolia Bioengineering Society. His research focuses on tumor immunology and pharmacological mechanisms of Mongolian medicine. Dr. Zhao has led multiple national and regional research projects, including studies on β-defensins, immune resistance, and cancer treatment mechanisms. His contributions to microbiology and oncology are widely recognized, with several impactful publications in international journals.

Professional Profile : 

Orcid

Scopus 

Summary of Suitability for Award:

Dr. Pengwei Zhao, a distinguished Professor at Inner Mongolia Medical University, has made significant contributions to tumor immunology, cancer pharmacology, and Mongolian medicine. His research on β-defensins and their role in immune modulation and cancer therapy has led to groundbreaking findings, particularly in colorectal and triple-negative breast cancer (TNBC). With numerous high-impact publications, including in Pharmacogenomics Journal and World Journal of Gastrointestinal Oncology, his work is recognized globally. His ongoing National Natural Science Foundation of China project further highlights his leadership in cancer research.  Dr. Pengwei Zhao’s extensive research, innovative methodologies, and interdisciplinary approach make him an outstanding candidate for the “Best Researcher Award”. His contributions to immunotherapy, autophagy, and microbiome-related cancer treatments have the potential to shape future oncological therapies. Recognizing him with this award would honor his pioneering discoveries and impact on global cancer research.

🎓Education:

Dr. Pengwei Zhao holds a Ph.D. in Basic Medical Sciences with a specialization in tumor immunology and pharmacology. His doctoral research focused on β-defensin-mediated immune modulation and cancer therapy. He pursued his higher education at Inner Mongolia Medical University, where he developed expertise in molecular biology, pharmacology, and immunology. His early education emphasized microbiology and traditional Mongolian medicine. Dr. Zhao further enhanced his skills through postdoctoral research and collaborations with leading scientists in cancer biology. His education provided a strong foundation in oncological pharmacology, signaling pathways, and immune resistance mechanisms. He has continuously expanded his knowledge through national and international conferences, workshops, and training programs. His academic journey reflects a commitment to translational research, bridging basic science with clinical applications in cancer therapy.

🏢Work Experience:

Dr. Zhao has been a Professor at Inner Mongolia Medical University for several years, where he also serves as a Master’s Supervisor. His professional roles extend beyond teaching, as he holds multiple directorial positions in national and regional scientific societies. He is a reviewer for prestigious journals, including Medical Science Monitor and Chinese Journal of Digestive Diseases. As a youth editorial board member of Modern Oncology, he actively contributes to cancer research. He has successfully led multiple research projects funded by national and regional agencies, focusing on cancer immunology, microbiology, and Mongolian medicine-based therapies. Additionally, Dr. Zhao has conducted collaborative research on β-defensins, autophagy, and immune resistance mechanisms. His expertise in pharmacological pathways and microbial interactions has significantly advanced the understanding of cancer treatment. He has also been invited as a speaker and panelist at various oncology and pharmacology conferences.

🏅Awards: 

Dr. Pengwei Zhao has received multiple prestigious awards and honors in recognition of his contributions to tumor immunology and Mongolian medicine research. He has been honored by the Inner Mongolia Medical University for excellence in research and mentorship. His work on β-defensins and their role in cancer has earned him accolades from Inner Mongolia’s Science and Technology Department. He has also received distinguished reviewer awards from journals such as Medical Science Monitor and Chinese Journal of Tissue Engineering Research. As a key member of the Chinese Society of Ethnomedicine and Pharmacy, he has been acknowledged for his research on the pharmacological mechanisms of traditional Mongolian medicine. His contributions to microbiology and immunology have been recognized by the Inner Mongolia Microbiology Society, and he has been invited as a young committee member of the Chinese Microbiological Society’s Clinical Microbiology Professional Committee.

🔬Research Focus:

Dr. Pengwei Zhao’s research primarily focuses on tumor immunology, cancer pharmacology, and the therapeutic potential of Mongolian medicine. He investigates the molecular mechanisms of β-defensins in cancer, particularly their role in immune regulation and tumor suppression. His work explores how β-defensin-1 peptides modulate PD-1/PD-L1 immune resistance in colorectal cancer. Additionally, he studies Mongolian medicinal formulations like Sendeng-4 and their mechanisms against skin cancer. His research also extends to microbiology, analyzing how bacterial infections, such as those caused by Staphylococcus aureus and Klebsiella pneumoniae, influence lung epithelial immune responses. Dr. Zhao has also contributed significantly to understanding long noncoding RNAs (lncRNAs) and their regulatory impact on autophagy pathways in cancer. His interdisciplinary approach integrates immunology, molecular biology, and ethnopharmacology, providing novel insights into cancer therapy, host-pathogen interactions, and the development of targeted immunotherapies.

Publication Top Notes:

Upregulation of p300 in paclitaxel-resistant TNBC: implications for cell proliferation via the PCK1/AMPK axis

Authors: P. Zhao, Pengwei; J. Cui, Jiaxian; X. Wang, Xiumei

Journal: Pharmacogenomics Journal

Year: 2024

Citations: 2

Human β-defensin-1 affects the mammalian target of rapamycin pathway and autophagy in colon cancer cells through long non-coding RNA TCONS_00014506

Authors: Y. Zhao, Yuxin; Y. Cui, Yan; X. Li, Xinhong; L. Bao, Lili; P. Zhao, Pengwei

Journal: World Journal of Gastrointestinal Oncology

Year: 2024

Citations: 3

Effect of Staphylococcus aureus in pneumonia mouse model on promotion of mBD-3 expression through ERK1/2

Authors: Yongqing Ni, Xiaoduo Bi, Pengwei Zhao

Ligilactobacillus salivarius LZZAY01 accelerated autophagy and apoptosis in colon cancer cells and improved gut microbiota in CAC mice

Authors: Yang W, Li T, An S, Chen R, Zhao Y, Cui J, Zhang M, Lu J, Tian Y, Bao L, Zhao P

Journal: Microbiol Spectrum

Year: 2025

LPS Promoted HPMEC Autophagy by Suppression of the PI3K/Akt/mTOR through Inhibited TIMAP-Promoted Moesin Expression in Sepsis

Authors: Jili Wen, Pengwei Zhao, HuiJuan Ren, JunMin Wu

Journal: Journal of Biological Regulators and Homeostatic Agents

Year: 2023